Among the Lp(a) research highlights, presented at the American Heart Association Scientific Sessions 2025 (7-10 November, New Orleans), were a further analysis of data from the Phase 2 OCEAN(a)-DOSE study and new insights into the role of Lp(a) in myocardial inflammation, opportunities to address barriers to Lp(a) clinical trial recruitment, projections on the impact of Lp(a) lowering on coronary heart disease risk, and the potential impact of social deprivation on epigenetic modification of the LPA gene and changes in plasma Lp(a) levels.
- Olpasiran reduces Lp(a) irrespective of particle size
- Role for Lp(a) shown in myocardial inflammation
- Addressing barriers to clinical trial recruitment pay off
- Greater Lp(a) lowering may lead to greater CHD risk reduction
- Socioeconomic deprivation linked to epigenetic modification of LPA gene
Reports by Jenny Bryan
